**MicroRNA-21 and microRNA-34a in Relation to other biological markers in Egyptian Breast Cancer Female Patients**

Fatma A. Elrefaey1, Nadia Z. Shaban2, Nashwa K. Ibrahim3, Fatma H. El-Rashidy2, Ahmad S. Kodous3

1Clinical Pathology Department, National Cancer Institute, Cairo University, Egypt

2Biochemistry Department, Faculty of Science, Alexandria University, Egypt

3Radiation Biology Department, National Center for Radiation Research & Technology (NCRRT), Egyptian Atomic-Energy Authority (EAEA), Egypt

[f\_alrefay@yahoo.com](mailto:f_alrefay@yahoo.com)

**Abstract:** **Background:** Altered microRNAs (miRNAs) expression has an impact on cancer initiation and progression. There is an emerging evidence that circulating miR21 and miR34a may have a potential role in breast cancer (BC) diagnosis and prognosis. **Aim of the work:** The current study aimed at characterizing the expression pattern of miR21 and miR34a in BC female patients pre- and post chemotherapy and delineating their correlation with clinicopathological subtypes and other molecular biomarkers. **Patients and Methods:** Real time quantitative polymerase chain reaction (RQ PCR) was used to assess the relative expression of miR21 and miR34a in sera of 179 BC female patients in relation to 58 healthy females. **Results:** Circulating miR21 and miR34a showed significant upregulation of 5.1 fold change (p<0.001) and downregulation of -5.63 fold change, respectively (p<0.001). Data showed higher levels of miR21 in triple negative (TN), basal like subtype and stage III BC patients (p<0.001). Higher miR34a expression was demonstrated in triple positive, luminal A & B subtypes and stage I & II BC patients (p<0.001). MiR21 was directly correlated with Bcl2 level (p<0.001). There was direct correlation between miR34a, BRAC1, BRAC2 & p53 (p<0.001). MiR21expression decreased significantly postchemotherapy (p<0.001). A significant increase in miR34a level was detected after chemotherapy (p<0.001). **Conclusion:** Our data suggest a potential role of circulating miR21 and miR34a as molecular biomarkers in BC.

**[**Fatma A. Elrefaey, Nadia Z. Shaban, Nashwa K. Ibrahim, Fatma H. El-Rashidy, Ahmad S. Kodous. **MicroRNA-21 and microRNA-34a in Relation to other biological markers in Egyptian Breast Cancer Female Patients.** *Cancer Biology* 2017;7(2):31-39]. ISSN: 2150-1041 (print); ISSN: 2150-105X (online). <http://www.cancerbio.net>. 5. doi:[10.7537/marscbj070217.05](http://www.dx.doi.org/10.7537/marscbj070217.05).

**Keywords:** miR21, miR34a, Breast cancer, BRAC1, BRAC2, Bcl2, p53

**1. Introduction**

Breast cancer (BC) is the most common malignant neoplasm among women and the leading cause of cancer related death in females globally [1]. In 2012, an estimate of 522,000 females died from BC worldwide [2]. An Egyptian study showed that 29% of National Cancer Institute (NCI) patients were diagnosed as BC. Most of them are premenopausal and presented in advanced stage, which may be attributed to the minor role early detection plays in Egypt compared to Europe and North America where screening and early detection are important and have more appreciated role [3].

MicroRNAs (miRNAs) are a class of small noncoding endogenous single stranded RNA molecules, 18-25 nucleotides long, playing an important role in regulating gene expression by pairing with mRNA of protein coding genes [4]. Previous studies have reported that miRNAs dysregulation affects cancer initiation, invasion and metastasis [5, 6]. Circulating miRNAs are very promising biomarkers in cancer diagnosis and prognosis as they are stable, minimally invasive and have high predictive value [7, 8].

The miRNA-21 (miR-21) gene is present on chromosome 17q23.2. This region is often amplified in BC [9]. MiR-21 upregulation may promote tumor initiation and progression through affecting cell cycle differentiation and apoptosis [10]. MiR-21 is considered one of the most important onco-miRNAs. It has a significant role in diagnosis of bronchogenic carcinoma and Gastrointestinal tumors [11, 12]. Previous studies reported miR-21 upregulation in serum of BC female patients [13].

On the other hand, miRNA-34a (miR-34a) is one among a family of three miRNAs; miRNA-34a is expressed in all tissue types except lung, while miR-34b/c are only expressed in lung tissue [14]. MiR-34a is often reported as a tumor suppressor miRNA. It induces apoptosis through p53 dependant tumor suppressor network. Mir-34a is downregulated in most cancer types and it inhibits the expression of Bcl2, various cyclins and cyclin dependant kinases (CDKs) [15].

The current study was undertaken to investigate the potential value of miR-21 and miR-34a expression as diagnostic and prognostic biomarkers in BC. In addition, we investigated the relation between miR-21, miR-34a expression and other biological markers in BC as BRAC1, BRAC2, p53, Bcl2, clinical staging and pathological subtypes.

**2. Patients and methods**

**Patients:**

One hundred and seventy nine female patients who presented to Oncology Department, NCI, Cairo. All patients included in this study had a pathologically confirmed diagnosis of primary BC. Median age at diagnosis was 52 years (28.5-75). Fifty eight serum samples were collected from healthy females with a median age of 53.5 years (32-71). The study was approved by the NCI Ethical Committee. Written informed consent was obtained from all participants.

**Tissue samples preparation:**

Morphological assessment of hematoxylin & eosin stained sections prepared from formalin-fixed paraffin-embedded tissue blocks was performed. Elston and Ellis grading system for invasive carcinoma has been used to evaluate tumor grading [16]. Tumor staging (TNM) was reported according to the World Health Organization (WHO 2003) classification of breast tumors [17].

**Methods**

**Immunohistochemistry:**

Streptavidin/biotin immunoperoxidase technique has been used for immunohistochemichal staining (Dakocytomation, Glostrup, Denmark). Hormone receptors were evaluated using anti-ER (mouse monoclonal IgG, Santa Cruz Biotechnology, CA), anti-PR (rabbit polyclonal IgG, Santa Cruz Biotechnology, CA), anti-HER2 (mouse monoclonal IgG, Santa Cruz Biotechnology, CA) followed by secondary antibodies and Diamino Benzidine (DAB) substrate chromogen (DakoCytomation, Glostrup, Denmark) for visualization.

**Serum miRNA assays**

**RNA extraction:**

All blood samples were collected; lymphocytes wereseparated and suspended in trizol and immediately frozen in liquid nitrogen until use. Total RNA was extracted from blood specimens by trizol RNA isolation protocol. The quality of the RNA samples was determined by Nanodrop, USA. To eliminate genomic DNA contamination, total RNA was treated with DNase I before first strand cDNA synthesis, according to the manufacturer’s instructions [18].

Sample lysis was achieved with the addition of 600 uL of lysis-binding solution (Qiagen, GmbH, Hilden, Germany) to the blood pellet, then vortexed vigorously for 30 seconds producing a homogenate lysate. Sixty uL of miRNA homogenate additive (Qiagen, GmbH, Hilden, Germany) was added to the lysate, then vortexed for 10 seconds followed by incubation on ice for 10 minutes. 600 uL of acid-phenol: chloroform (Qiagen, GmbH, Hilden, Germany) was added to the lysate and vortexed for 30 seconds then centrifuged for 5mins at 10000g at Room Temperature (RT).

One-third volume of 100% ethanol was added to the recovered aqueous phase and total volume was passed through a fibre-glass filter cartridge via 15 seconds of centrifugation at 10000g. The filtrate collected containing small RNA molecules whereas the filter cartridge contained the large RNA molecule, each was processed separately [18, 19].

**Enrichment for small RNAs/ Collection of small RNAs – filtrate:**

Two-thirdvolume of absolute ethanol was added to the collected filtrate, then added to a new fibre-glass filter cartridge and centrifuged for 15 seconds at 10,000 g upon which the filtrate was discarded. The filter cartridge was then subjected to 3 washes (Qiagen, GmbH, Hilden, Germany) in which the flow-through was discarded on each occasion. Finally, 100 uL of Elution Solution, pre-heated at 95C, was added into the filter cartridge and centrifuged at 13000 g for 30 sec [18, 19].

**Collection of large RNAs:**

The original filter cartridge was subjected to 3washes in which the flow-through was discarded on each occasion. Finally 100 uL of elution solution (Qiagen, GmbH, Hilden, Germany), was added to the filter cartridge and centrifuged at 13000 g for 30 seconds [18, 19].

**MiRNA expression by Real-Time PCR:**

The expression of miRNAs(miR-21 & miR-34a) was evaluated by qRT-PCR analysis, according to the manufacturer’s directions. The housekeeping miRNA U6 RNA was used as an endogenous control. For RT-PCR, 5 µl of cDNA template was mixed with 12.5 µl of SYBR Green Master Mix (QIAGEN GmbH, Hilden, Germany), and nuclease free water was added to a final volume of 25 µl and dispensed into a 96-well miScript miRNA PCR array plate and enriched with forward and reverse miRNA specific primers. Real-time PCR was performed using an Applied Biosystems 7500 Real-time PCR System (AB, USA) under the following cyclic conditions: 95°C for 15 min, followed by 40 cycles of amplification at 95°C for 5 s and 60°C for 34 s. The data obtained from the miRNA expression levels were calculated and evaluated by the cycle threshold (Ct) method. The level of miRNA expression was reported as Ct value [20, 21]. Ct was calculated by subtracting the Ct of U6 RNA from the Ct of the miRNA of interest. The Ct was calculated by subtracting the Ct of the reference sample (normal breast) from the Ct of each sample. Fold change was generated using the equation 2− ∆∆Ct. A pool of 3 normal whole blood samples was used as reference sample for the Ct. The MicroRNA Assays for U6 RNA (RNU6; Applied Biosystems) was used to normalize the relative abundance of miRNA expression [21].

**Real time PCR for gene expression:**

Real time PCR for gene expression was performed on(Applied Biosystems7500) to detect expression of BRCA1, BRCA2, p53, and Bcl-2 genes. All reactions were run in triplicate and included no template and no reverse transcription controls for each gene. Cyclic conditions consisted of 15 s at 95˚C then 40 cycles of 5 sec at 95 ˚C and 1 min at 60˚C.

BRCA1, BRCA2, p53, and Bcl-2 mRNAs expression levels was measured according to Ct method for relative quantitation of gene expression. The Taqman mRNA Assays for GAPDH was used to normalize the relative abundance of BRCA1, BRCA2, p53, and Bcl-2 mRNAs [22].

**Statistical analysis**

Data was analyzed using IBM SPSS advanced statistics version 22 (SPSS Inc., Chicago, IL). Numerical data were expressed as mean and standard deviation or median and range as appropriate. Qualitative data were expressed as frequency and percentage. For not normally distributed quantitative data, comparison between two groups was done using Mann-Whitney test (non-parametric t-test). Comparison between more than two groups was done using Kruskal-Wallis test (non-parametric ANOVA) then post-Hoc "Schefe test" was used for pair-wise comparison based on Kruskal-Wallis distribution. Spearman-rho method was used to test correlation between numerical variables. Wilcoxon-signed ranks test (non-parametric paired t-test) was used to compare two consecutive measures of numerical variables. All tests were two-tailed. A p-value < 0.05 was considered significant.

**3. Results**

This study included 179 BC female patients and 58 healthy controls. Both patients and controls were matched for age; median age 52 (28.5- 75) & 53.5 (32-71), respectively.

**Characteristics of the patients:**

All BC cases had a confirmed pathological diagnosis (31 carcinoma in situ and 148 invasive carcinoma). Table 1 shows patients characteristics.

Median miR-21 was significantly upregulated at time of diagnosis with 5.1 fold change in patients vs. controls (p<0.001). Whereas, median miR-34a showed significant downregulation of -5.63 fold change in patients vs. controls (p<0.001).

Median miR-34a, BRAC1, BRAC2 & p53 fold expression were significantly higher in ER+ve, PR+ve & HER-2 +ve patients vs. ER-ve, PR-ve & HER-2-ve patients pre and post chemotherapy (p <0.001). Median miR-21 & BCL-2 fold expression were significantly lower in ER+ve, PR +ve & HER-2 +ve patients vs. ER-ve, PR-ve & HER-2 -ve patients, respectively pre and post chemotherapy (p <0.001) (Table 2).

Median miR-34a, BRAC1, BRAC2, p53 fold expression pre and post chemotherapy were significantly lower in basal like vs. luminal A & B and HER2/neu subtypes. (p <0.001) whereas median miR21 and BCL2 fold expression pre and post chemotherapy were significantly higher in basal like vs. luminal A & B and HER2/neu subtypes (p <0.001) (Table 3).

Median miR-34a, BRAC1, BRAC2, p53 fold expression pre and post chemotherapy were significantly lower in stage III vs. I/II (p <0.001) whereas median mir21 and bcl2 fold expression pre and post chemotherapy were significantly higher in stage III vs. I/II (p <0.001). From all biological markers studied, only median BRAC1 fold expression pre chemotherapy was significantly higher in stage I vs. stage II (Table 4).

Table (1): Clinicopathological Characteristics of the patients

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristics** | | **Number** | **%** |
| **ER** | **Positive** | 112 | 63 |
|  | **Negative** | 67 | 37 |
| **PR** | **Positive** | 106 | 59 |
|  | **Negative** | 73 | 41 |
| **Her2 neu** | **Positive** | 63 | 35 |
|  | **Negative** | 116 | 65 |
| **Subtypes** | **Luminal A** | 66 | 37 |
|  | **Luminal B** | 47 | 26 |
|  | **Basal Like** | 50 | 26 |
|  | **Her2/neu** | 16 | 9 |
| **T** | **T1** | 12 | 7 |
|  | **T2** | 136 | 76 |
|  | **T3** | 31 | 17 |
| **N** | **0** | 12 | 7 |
|  | **1** | 135 | 75 |
|  | **2** | 18 | 10 |
|  | **3** | 14 | 8 |
| **M** | **0** | 179 | 100 |
|  | **1** | 0 | 0 |
| **Clinical Stage** | **I** | 12 | 7 |
|  | **II** | 135 | 75 |
|  | **III** | 32 | 18 |

**Difference in fold change expression post chemotherapy:**

Median miR34a, miR21, BRAC1, BRACA2, P53 and BCL2 difference in fold change expression after therapy (post- pre) were 5.48 (-0.72: 9.38), 5.79 (0.77: 10.5), -5.88 (-8.51: 0.30), 6.25 (-0.77: 8.94), 7.55 (-0.34: 10.14) and -8.47 (-11.19: 1.56), respectively. MiR34a difference in fold change expression was directly correlated with BRAC1, BRAC2 & p53 and inversely correlated with miR21 and Bcl2 (Table 5).

Table (2): Median Markers Expression in ER, PR, HER2/neu in 179 BC patients pre and post chemotherapy

Table (2a): Median miR-34a, BRACA1, BRCA2 and P53 expression

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  | **miR-34** | | **BRACA1** | | **BRCA2** | | **P53** | |
|  |  |  | **Pre** | **Post** | **Pre** | **Post** | **Pre** | **Post** | **Pre** | **Post** |
| **ER** | **Positive N=112** | Median | -14.93 | -8.28 | -16.56 | -10.85 | -13.18 | -7.11 | -13.36 | -5.21 |
| Range | -16.56 to -13.83 | -14.83 to -7.06 | -19.97 to -14.32 | -18.64 to -9.25 | -16.34 to -12.04 | -14.42 to -5.82 | -17.63 to -11.71 | -13.55 to -4.11 |
| **Negative N=67** | Median | -16.0 | -13.18 | -19.7- | -18.38 | -16.56 | -14.32 | -16.34 | -13 |
| Range | -17.51 to -13.64 | -15.67 to -7.01 | -21.86 to -15.14 | -21.26 to -9.51 | -18.38 to -12.55 | -16.45 to -6.54 | -19.16 to -11.71 | -16.34 to -4.17 |
| **PR** | **Positive N=106** | Median | -14.93 | -8.28 | -16.51 | -10.85 | -13.18 | -7.11 | -13.36 | -5.19 |
| Range | -2.73 | -14.83 to -7.06 | -19.97 to -14.32 | -18.64 to -9.25 | -16.34 to -12.04 | -14.42 to -5.82 | -17.63 to -11.71 | -13.55 to -4.11 |
| **Negative N=73** | Median | -15.78 | -13 | -19.43 | -18.25 | -16.34 | -14.22 | -16.22 | -12.82 |
| Range | -17.51 to -13.64 | -15.67 to -7.01 | -21.86 to -15.14 | -21.26 to -9.51 | -5.83 | -16.45 to -6.54 | -19.16 to -11.71 | -16.34 to -4.17 |
| **HER2-neu** | **Positive N=63** | Median | -14.93 | -8.28 | -16.56 | -10.85 | -13.27 | -7.11 | -13.36 | -5.1 |
| Range | -16.45 to -13.74 | -14.83 to -7.01 | -19.97 to -15.14 | -18.64 to -9.32 | -16.34 to -12.04 | -14.42 to -5.82 | -17.63 to -11.71 | -13.55 to -4.26 |
| **Negative N=116** | Median | -15.45 | -9.06 | -18.38 | -11.55 | -13.69 | -7.36 | -14.12 | -6.11 |
| Range | -17.51 to -13.64 | -15.67 to -7.26 | -21.86 to -14.32 | -21.26 to -9.25 | -18.38 to -12.04 | -16.45 to -5.98 | -19.16 to -11.71 | -16.34 to -4.11 |

Table (2b): Median miR-21 and Bcl2 Expression

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | | | **miR-21** | | **Bcl2** | |
| **Pre** | **Post** | **Pre** | **Post** |
| **ER** | **Positive**  **N=112** | Median | 17.39 | 11 | 14.67 | 5.94 |
| Range | (15.35 - 22.63) | (9 - 19.29) | (13.09 - 20.25) | (5.13 - 9.06) |
| **Negative**  **N=67** | Median | 20.53 | 19.03 | 18.13 | 14.62 |
| Range | (15.67 - 23.59) | 9.00 - 22.16 | 13.55 - 21.11 | 5.21 - 17.88 |
| **PR** | **Positive**  **N=106** | Median | 17.39 | 11 | 14.62 | 5.94 |
| Range | 15.35 - 22.63 | 9.0 - 19.29 | 13.9 - 20.25 | 5.13 - 9.6 |
| **Negative**  **N=73** | Median | 20.53 | 18.9 | 18 | 14.52 |
| Range | 15.67 - 23.59 | 9.00 - 22.16 | 13.55 - 21.11 | 5.21 - 17.88 |
| **HER2-neu** | **Positive**  **N=63** | Median | 17.39 | 11 | 14.83 | 5.86 |
| Range | 15.56 - 22.63 | 9.0 - 19.29 | 13.36 - 20.25 | 5.13 - 9.06 |
| **Negative N=116** | Median | 18.19 | 12 | 15.3 | 6.36 |
| Range | 15.35 - 23.59 | 9 - 22.16 | 13.09 - 21.11 | 5.17 - 17.88 |

Table (3): Median Markers Expression in different pathological subtypes and clinical stages in 179 BC patients' pre and post chemotherapy

Table (3a): Median miR-34, BRACA1, BRCA2 and P53 expression

|  |  |  | **miR-34** | | **BRCA1** | | **BRACA2** | | **P53** | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  | **Pre** | **Post** | **Pre** | **Post** | **Pre** | **Post** | **Pre** | **Post** |
| **Subtypes** | **Luminal A**  **(N=66)** | Median | -14.93 | -8.4 | -16.45 | -10.93 | -13.22 | -7.06 | -13.41 | -5.21 |
|  | Range | -16.56 to -14.03 | -11.08 to -7.26 | -18.77 to -14.32 | -12.73 to -9.25 | -14.22 to -12.04 | -8.17 to -5.98 | -15.14 to -11.71 | -7.31 to -4.11 |
| **Luminal B (N=47)** | Median | -14.93 | -8.17 | -17.15 | -10.85 | -13 | -7.11 | -13.36 | -5.21 |
|  | Range | -16.34 to -13.83 | -14.83 to -7.06 | -19.97 to -15.35 | -18.64 to -9.32 | -16.34 to -12.04 | -14.42 to -5.82 | -17.63 to -11.71 | -13.55 to -4.26 |
| **HER2/neu (N=16)** | Median | -15.3 | -8.31 | -16.28 | -10.74 | -13.55 | -7.14 | -13.22 | -5.01 |
|  | Range | -16.45 to -13.74 | -10.93 to -7.01 | -18.64 to -15.14 | -12.73 to -9.85 | -14.22 to -12.55 | -7.52 to 6.54 | -15.03 to -11.71 | -6.96 to -4.41 |
| **Basal like**  **(N=50)** | Median | -16.22 | -13.64 | -20.46 | -18.77 | -17.15 | -14.62 | -16.8 | -13.32 |
|  | Range | -17.51 to -13.64 | -15.67 to -7.31 | -21.86 to -16.22 | -21.26 to -9.51 | -18.38 to -13.36 | -16.45 to -7.01 | -19.16 to -11.71 | -16.34 to -4.17 |
| **Clinical Stages** | **Stage I (N=12)** | Median | -15.09 | -8.06 | -15.56 | -10.74 | -13.36 | -7.09 | -13.88 | -4.92 |
|  | Range | -16.00 to -13.83 | -9.00 to -7.01 | -15.78 to -14.32 | -11.55 to -9.32 | -14.22 to -12.04 | -7.36 to -6.63 | -15.03 to -12.21 | -6.36 to -4.41 |
| **Stage II (N=135)** | Median | -15.03 | -8.4 | -17.75 | -10.93 | -13.27 | -7.16 | -13.55 | -5.31 |
|  | Range | -17.15 to -13.64 | -15.67 to -7.16 | -20.53 to -15.35 | -21.26 to -9.25 | -18.38 to -12.04 | -15.67 to -5.82 | -19.16 to -11.71 | -16.00 to -4.11 |
| **Stage III (N=32)** | Median | -16 | -13.64 | -20.98 | -19.16 | -17.15 | -14.42 | -16.91 | -13.09 |
|  | Range | -17.51 to -14.42 | -15.03 to -7.89 | -21.86 to -19.7 | -21.26 to -17.88 | -18.13 to -15.78 | -16.45 to -7.01 | -18.51 to -11.71 | -16.34 to -4.17 |

Table (3b): Median miR-21 and Bcl2 expression

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  |  | **miR-21** | | **BCL2** | |
|  |  |  | **Pre** | **Post** | **Pre** | **Post** |
| **Subtypes** | **Luminal A**  **(N=66)** | Median | 17.21 | 11.04 | 14.62 | 5.94 |
|  | Range | 15.35 – 19.03 | 9.0 – 13.0 | 13.09 – 16.11 | 5.17 – 6.68 |
| **Luminal B (N=47)** | Median | 17.51 | 10.85 | 14.93 | 5.86 |
|  | Range | 15.56 – 22.63 | 9.00 – 19.29 | 13.36 – 20.25 | 5.13 – 9.06 |
| **HER2/neu (N=16)** | Median | 17.09 | 11.16 | 14.52 | 5.88 |
|  | Range | 15.78 – 18.77 | 9.25 – 12.55 | 13.55 – 16.11 | 5.21 – 6.92 |
| **Basal like**  **(N=50)** | Median | 21.04 | 19.7 | 18.83 | 15.35 |
|  | Range | 15.67 – 23.59 | 9 – 22.16 | 13.93 – 21.11 | 5.21 – 17.88 |
| **Clinical Stages** | **Stage I (N=12)** | Median | 17.39 | 11 | 14.57 | 5.94 |
|  | Range | 16.11 – 18.64 | 9.25 – 12.04 | 13.93 – 15.89 | 5.21 – 6.36 |
| **Stage II (N=135)** | Median | 17.51 | 11.31 | 14.83 | 5.98 |
|  | Range | 15.35 – 22.63 | 9.00 – 22.16 | 13.09 – 20.97 | 5.13 – 17.15 |
| **Stage III (N=32)** | Median | 20.97 | 19.7 | 18.7 | 15.35 |
|  | Range | 15.67 – 23.59 | 9.00 – 21.86 | 13.93 – 21.11 | 5.21 – 17.88 |

Table (4): Correlation between gene fold expression of miR 34a, miR21, BRAC1, BRAC2, p53 and Bcl2 (A) pre-chemotherapy (B) post-chemotherapy

(A) Pre-chemotherapy

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **BRAC1** | **BRAC2** | **miR-21** | **miR-34a** | **P53** |
| **BRACA2 r** | 0.571 |  |  |  |  |
| **miR-21 r** | -0.469 | -0.538 |  |  |  |
| **miR34 r** | 0.432 | 0.434 | -0.489 |  |  |
| **P53 r** | 0.487 | 0.424 | -0.549 | 0.536 |  |
| **BCL2 r** | -0.439 | -0.509 | 0.930 | -0.482 | -0.530 |

(P <0.001)

B) Post-chemotherapy

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **BRAC1** | **BRAC2** | **miR-21** | **miR-34a** | **P53** |
| **BRACA2 r** | 0.608 |  |  |  |  |
| **miR-21 r** | -0.544 | -0.512 |  |  |  |
| **miR34 r** | 0.643 | 0.514 | -0.55 |  |  |
| **P53 r** | 0.547 | 0.467 | -0.536 | 0.639 |  |
| **BCL2 r** | -0.542 | -0.539 | 0.9 | -504 | -0.462 |

(P <0.001)

Table (5): Correlation between difference in fold change expression of BRAC1, BRAC2, miR21, miR34, p53 and BCL2 (post-pre)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **BRAC1** | **BRAC2** | **miR-21** | **miR-34a** | **P53** |
| **BRACA2 r** | 0.535 |  |  |  |  |
| **miR-21 r** | -0.463 | -0.47 |  |  |  |
| **miR34 r** | 0.556 | 0.512 | -0.549 |  |  |
| **P53 r** | 0.556 | 0.483 | -0.549 | 0.609 |  |
| **BCL2 r** | -0.462 | -0.444 | 0.815 | -532 | -0.509 |

Median miR-34, BRAC1, BRAC2 & p53 difference in fold change expression were significantly higher in ER+ve, PR+ve & HER-2 +ve patients vs. ER-ve, PR-ve & HER-2-ve patients (p<0.001). Median miR-21 & BCL-2 difference in fold change expression were significantly lower in ER+ve, PR +ve & HER-2 +ve patients vs. ER-ve, PR-ve & HER-2 -ve patients (p<0.001).

Median miR-34, BRAC1, BRAC2 & p53 difference in fold change expression were significantly lower in basal like vs. luminal A & B and HER2/neu subtypes. (p=<0.001) whereas median mir21 and bcl2 difference in fold change expression were significantly higher in basal like vs. luminal A & B and HER2/neu subtypes (p<0.001).

Median miR-34, BRAC1, BRAC2 & p53 difference in fold change expression were significantly lower in stage III vs I/II (p=<0.001) whereas median mir21 and bcl2 difference in fold change expression were significantly higher in stage III vs. I/II (p<0.001). (Table 6).

A statistically significant direct correlation was found between age of the patients and miR34a, miR21, BRAC1, BRAC2, and p53 gene expression fold, whereas an inverse correlation was found between age and miR21 and bcl2 pre, post chemotherapy and fold change (Table 6).

Table (6): Difference in median markers fold change expression (post-pre) in relation to ER, PR, Her2, subtypes and Clinical stages

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  | **mirR-34** | **BRACA1** | **BRACA2** | **P53** | **miR-21** | **BCL2** |
| **ER** | **Positive**  **N=112** | Median | 6.63 | 6.07 | 6.02 | 7.88 | -6.28 | -8.79 |
|  |  | Range | 1.51 – 8.94 | 1.34 – 9.38 | 1.92 – 7.58 | 4.08 – 10.14 | -8.51 to -3.32 | -11.19 to - 6.77 |
|  | **Negative**  **N=67** | Median | 3.08 | 1.89 | 2.7 | 4.32 | -2.19 | -4.08 |
|  |  | Range | 0.77 – 8.54 | -0.72 – 8.25 | 0.77– 10.5 | -0.34 – 9.62 | -7.66 to -0.3 | -9.52 to -1.56 |
| **PR** | **Positive**  **N=106** | Median | 6.63 | 6.07 | 6.03 | 7.89 | -6.26 | -8.79 |
|  |  | Range | 1.51– 8.94 | 1.34 – 9.38 | 1.92– 7.58 | 4.08 – 10.14 | -8.51 to -3.32 | -11.19 to -6.77 |
|  | **Negative**  **N=73** | Median | 3.27 | 2.11 | 2.93 | 4.48 | -2.57 | -4.2 |
|  |  | Range | 0.77 – 8.54 | -0.72 – 8.25 | 0.77 – 10.5 | -0.34 – 9.65 | -7.66 to -0.3 | -9.52 to -1.56 |
| **HER2-neu** | **Positive**  **N=63** | Median | 6.57 | 6.08 | 6.04 | 7.93 | -6.21 | -8.84 |
|  |  | Range | 1.51– 8.94 | 1.34 – 8.04 | 1.92 – 7.45 | 4.08 – 9.82 | -8.51 to -3.33 | -11.19 to -7.42 |
|  | **Negative N=116** | Median | 6.07 | 4.81 | 5.55 | 7.27 | -5.45 | -8.25 |
|  |  | Range | 0.77 – 8.72 | -0.72to9.38 | 0.77 – 10.5 | -0.34 to 10.14 | -8.51 to 0.3 | -10.42 to -1.56 |
| **Subtypes** | **Luminal A (N=66)** | Median | 6.63 | 6.04 | 6.13 | 7.87 | -6.28 | -8.72 |
|  |  | Range | 3.96 – 8.72 | 3.47 – 9.38 | 4.68 – 7.58 | 5.56 – 10.14 | -8.51 to -3.32 | -10.42 to 6.77 |
|  | **Luminal B (N=47)** | Median | 6.46 | 6.24 | 6 | 7.93 | -6.26 | -9.2 |
|  |  | Range | 1.51 – 8.94 | 1.34 – 8.04 | 1.92 – 7.45 | 4.08 – 9.82 | -8.51 to -3.33 | -11.19 to -7.42 |
|  | **HER2/neu (N=16)** | Median | 2.76 | 1.42 | 2.34 | 3.62 | -1.5 | -3.65 |
|  |  | Range | 0.77 – 7.41 | -0.72 – 8.25 | 0.77 – 10.5 | -0.34 to -8.48 | -7.48 to 0.3 | -9.37 to -1.56 |
|  | **Basal like (N=50)** | Median | 7 | 5.8 | 6.43 | 8.15 | -6.06 | -8.73 |
|  |  | Range | 4.85 – 8.54 | 4.51 – 7.53 | 5.32 – 7.06 | 6.68 – 9.62 | -7.66 to -4.54 | -9.52 to -7.79 |
| **Clinical Stages** | **Stage I (N=12)** | Median | 6.91 | 4.72 | 6.24 | 8.59 | -6.25 | -8.82 |
|  |  | Range | 5.93 – 8.94 | 3.47 – 6.24 | 4.88 – 7.34 | 7.16-10.11 | -8.51 to -5.11 | -10.47 to -7.79 |
|  | **Stage II (N=135)** | Median | 6.45 | 6.04 | 5.95 | 7.68 | -6.03 | -8.63 |
|  |  | Range | 0.77 – 8.72 | -0.72 – 9.38 | 0.77 – 7.58 | 1.99 – 10.14 | -8.51 to 0.14 | -11.19 to -2.75 |
|  | **Stage III (N=32)** | Median | 2.81 | 1.74 | 2.43 | 3.94 | -1.59 | -3.49 |
|  |  | Range | 0.97 - 7.04 | -0.28 to 33 | 1.06 – 10.5 | -0.34 to 8.48 | -7.48 to 0.3 | -9.3 to - 1.56 |

(p<0.001)

**Table (6): Correlation between biological markers and age pre, post chemotherapy & difference in fold change expression (post-pre)**

|  |  |  |
| --- | --- | --- |
|  |  | r |
| **BRAC1** | Pre | 0.585 |
|  | Post | 0.606 |
|  | Difference change | 0.543 |
| **BRACA2** | Pre | 0.544 |
|  | Post | 0.556 |
|  | Difference Change | 0.515 |
| **miR-21** | Pre | -0.438 |
|  | Post | **-0.456** |
|  | Difference Change | 0.461 |
| **miR-34a** | Pre | 0.314 |
|  | Post | 0.434 |
|  | Difference Change | 0.485 |
| **P53** | Pre | 0.416 |
|  | Post | 0.562 |
|  | Difference Change | 0.558 |
| **Bcl2** | **Pre** | -0.405 |
|  | Post | -0.429 |
|  | Difference Change | -0.478 |

**4. Discussion**

Evidence proved that several miRNAs exhibit dysregulated expression in BC. In this study, we investigated the relative expression of circulating miR-21 and miR-34a in the serum of 179 BC female patients.

Our study showed a significantly higher relative expression of miR-21 and a remarkably lower relative expression of miR-34a in BC patients compared to normal females. The study of Iorio et al was the first to report miR-21 upregulation in the serum of BC patients in relation to healthy controls [13]. A variation in miR34a expression level in different tumor types has been reported. In consistent with our results Bommer et al and Javeri et al reported that miR-34a was downregulated in different cancer types including GIT tumors, BC and neuroblastomas. [14, 23] On the contrary, Roth et al showed an overexpression of miR-34a in BC patients; we could not find an explanation for this contradiction [24].

We demonstrated in our study that miR34a expression was significantly higher in patients with positive ER, PR and HER-2 and lower in triple negative (TN) patients. Also, Brian et al demonstrated that miR-34a levels were lower in TNBC cell lines [25]. In our study, we found an upregulation of miR21 expression in TNBC patients. Similarly to our results, Hong Fang et al have found that miR-21 was upregulated in TN patients [26].

In this study, miR-21 was inversely correlated with BRAC1, BRAC2 and p53 expression. On the contrary, its expression was significantly correlated with BCL2. However, this correlation was not reported by others.

On the other hand, miR34a expression showed a direct correlation with the tumor suppressor genes BRAC1, BRAC2 and p53 while it showed an inverse correlation with BCL2. Li L. et al stated similar results and concluded that miR-34a is able to inhibit BC cell proliferation and migration through downregulation of Bcl-2 [27].

We found that miR34a was significantly downregulated in stage III versus I and II and in basal cell subtype versus luminal A & B. Our results were in agreement with Peurala and colleagues [28]. We found that miR-21 was upregulated in advanced clinical stages and lymph node metastasis. This finding was also in agreement with Li Xu et al [29].

Our study demonstrated an increased expression of miR-34a post chemotherapy; similar results were reported by Pierre et al [30]. Supporting our results, Gong et al reported a significant downregulation of miR-21 after chemotherapy which showed that it acts as an onco miRNA in BC [31].

Our results support that miR-34a acts as a tumor suppressor miRNA in BC and that it possesses an anti-tumor effect while it suggests that miR21 acts as an onco-miRNa.

In conclusion, miR-21 and miR-34a, as minimally invasive molecular markers, show altered circulating levels in BC patients compared to healthy controls and a remarkable correlation with other biological markers. However, future studies are recommended to confirm and further delineate the potential role of miR-21 and miR-34a as novel diagnostic and prognostic biomarkers in BC.

**References:**

1. De Santis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014 CA Cancer J Clin. 2014;64(4): 252-71. Doi: 10.3322/caac.21235.
2. Dany RY, Susanna MC, Cheng HY, Baade PD, et al. Incidence and mortality female breast cancer in the Asia- Pacific region. Cancer Biol Med. 2014;11:101-15. Doi:10.7497/j.issn.2095-3941. 2014.02.005.
3. Allam MF, Abd Elaziz KM. Evaluation of the level of knowledge of Egyptian women of breast cancer and its risk factors. A cross sectional study. J Prev Med Hyg. 2012; 53(4): 195-198.
4. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33.
5. Weiland M, Gao XH, Zhou L, et al. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol. 2012;9(6):850–9.
6. Zhang J, Zhao H, Gao Y, et al. Secretory miRNAs as novel cancer biomarkers. Biochim Biophys Acta. 2012;1826(1):32–43.
7. Heneghan HM, Miller N, Lowery AJ, et al. Circulating micrornas as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010;251(3):499–505.
8. Patrick SM, Rachael KP, Evan MK, et al. Circulating microRNAs as stable blood-basedmarkers for cancer detection. Proc Natl Acad Sci USA. 2008;105(30):10513–8.
9. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 2004;101:2999–3004.
10. Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat. 2009;117:131–40.
11. Li T, Leong MH, Harms B, et al. MicroRNA-21 as a potential colon and rectal cancer biomarker. World J Gastroenterol. 2013;19(34):5615–21.
12. Zeng ZY, Wang JG, Zhao LY, et al. Potential role of micro RNA-21 in the diagnosis of gastric cancer: a meta-analysis. PLoS One. 2013;8(9):e73278.
13. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16): 7065-70.
14. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, MacDougald OA, Cho KR, Fearon ER. p53- mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 2007; 17:1298-1307.
15. Ghawanmeh T, Thunberg U, Castro J, Murray F, Laytragoon-Lewin N (2011) miR-34a expression, cell cycle arrest and cell death of malignant mesothelioma cells upon treatment with radiation, Docetaxel or combination treatment. Oncology 81(5–6):330–335.
16. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer:experience from a large study with long-term follow-up. Histopathology. 1991; 19:403–10.
17. Tavassoe ́liFA, Devilee P. Pathology and genetics: Tumours of the breast and female genital organs (WHO Classification of Tumors). IARC Press. 2003; p10.
18. Chen, C., Ridzon, D.A., Broomer, A.J., Zhou, Z., Lee, D.H., Nguyen, J.T., Barbisin, M., Xu, N.L., Mahuvakar, V.R., Andersen, M.R. and Lao, K.Q. Real-time quantification of microRNAs by stem-loop RT-PCR. *Nucleic acids research* 2005;33(20):e179.
19. Heneghan H, Miller N, Lowery A, Karl J, Newell J, Michael J. Circulatory microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010; 251(3):499–505.
20. Jiang J, Lee EJ, Gusev Y, et al (2005). Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res, **33**, 5394-403.
21. Livak, K. J., Schmittgen T. D., 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods. (4):402-8.
22. Kesavan, Sabitha, Ahmad Kodous, and Thangarajan Rajkumar. "Computational analysis of mutations in really interesting new gene finger domain and BRCA1 c terminus domain of breast cancer susceptibility gene." Asian Journal of Pharmaceutical and Clinical Research (2016), 9 (3):96-102.
23. Javeri A, Ghaffarpour M, Taha MF, Houshmand M. Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis. Med Oncol. 2013; 30:413.
24. Roth C, Rack B, Müller V, Janni W, Pantel K, Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Research. 2010; 12:R90.
25. Brian D. Adams, vikram B. Wali, Christopher J. Cheng, Sachi Inukai, Carmen J. Booth, Seema Agarwal, et al. miR-34a Silences c-SRC to attenuate tumor growth in triple negative breast cancer. Cancer Res. 2016;76(4):927-939.
26. Hong Fang, Jiping Xie, Min Zhang, Ziwei Ahao, Yi Wan, and Youngqiang Yao. Am J Transl Res. 2017; 9(3): 953-961.
27. Li L., Yuan L., Luo J., Gao J., Guo J., Xie X., et al. MiR34a inhibits proliferation and migration of breast cancer through downregulation of Bcl-2 and SIRTI. Clin. Exp. Med. 2012 in press.
28. Peurala H, Greco D, Heikkinen T, Kaur S, Bartkova J, Jamshidi M, Aittomaki K, Heikkila P, Bartek J, Blomqvist C, Butzow R, Nevanlinna H (2011) MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer. *PLoS One* **6**(11): e26122.
29. Li-Xu Yan, Xiu-Fang Haung, Qiong Shao, Ma-Yan Haung, Ling Deng, Qiu-Liang Wu, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008;14(11): 2348-2360.
30. Pierre Frères, Claire Josse, Nicolas Bovy, Meriem Boukerroucha, Ingrid Struman, Vincent Bours, Guy Jerusalem. Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression. 2015;230(2):473–481.
31. Gong G, Yao Y, Wang Y, et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Bio I Chem. 2011;286(21):19127-19137.

6/21/2017